TAC1

(redirected from Neurokinin 1)

TAC1

A gene on chromosome 7q21-q22 that encodes four different tachykinins—substance P, neurokinin A, neuropeptide K and neuropeptide gamma—which are thought to function as neurotransmitters, interacting with nerve receptors and smooth muscle cells, inducing behavioural responses and acting as vasodilators and secretagogues.
Mentioned in ?
References in periodicals archive ?
Knoth This retrospective cohort analysis compared the incidence of CINV in patients undergoing chemotherapy and treated prophylactically with either intravenous (IV) palonosetron alone or other 5HT3RAs in combination with an IV or oral neurokinin 1 receptor antagonist (NK1).
Neurokinin 1 receptor antagonism as a possible therapy for alcoholism.
Substance P induces vomiting and binds to neurokinin 1 (NK-1) receptors in the abdominal vagus, the nucleus tractus solitarius, and the area postrema.
For OIH, proposed mechanisms include a role for glutaminergic activation (also implicated in tolerance), altered opioid intracellular signalling involving G protein-coupled receptor switching, a role for substance P and neurokinin 1 (NK-I) receptors and spinal dynorphin and, finally, increasing evidence implicating Toll-like receptor (TLR) signalling and glial cells.
In addition, researchers are evaluating the therapeutic potential of corticotrophin-releasing factor antagonists and neurokinin 1 antagonists, which may address the relationship between stress and alcohol consumption.
current neurokinin 1 receptor antagonists) offer promise for more specific and possibly more effective and long-lasting treatment efficacy.
Contribution of neurokinin 1 receptors in the cutaneous orofacial cutaneous pain.
Tradipitant, formerly known as VLY-686, is a neurokinin 1 receptor antagonist under clinical investigation for the treatment of chronic pruritus in patients with atopic dermatitis.
Neurokinin 1 (NK1) Receptor and Substance P Antagonists
Direct observation of substance P-induce internalization of neurokinin 1 (NK1) receptors sites of inflammation.
The drug--the first in a new class of medicines--is a substance P / neurokinin 1 receptor antagonist.